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The Mas oncogene encodes a novel G-protein-coupled receptor that was identified originally as a trans-
forming protein when overexpressed in NIH 3T3 cells. The mechanism and signaling pathways that mediate
Mas transformation have not been determined. We observed that the foci of transformed NIH 3T3 cells caused
by Mas were similar to those caused by activated Rho and Rac proteins. Therefore, we determined if Mas
signaling and transformation are mediated through activation of a specific Rho family protein. First, we
observed that, like activated Rac1, Mas cooperated with activated Raf and caused synergistic transformation
of NIH 3T3 cells. Second, both Mas- and Rac1-transformed NIH 3T3 cells retained actin stress fibers and
showed enhanced membrane ruffling. Third, like Rac, Mas induced lamellipodium formation in porcine aortic
endothelial cells. Fourth, Mas and Rac1 strongly activated the JNK and p38, but not ERK, mitogen-activated
protein kinases. Fifth, Mas and Rac1 stimulated transcription from common DNA promoter elements: NF-kB,
serum response factor (SRF), Jun/ATF-2, and the cyclin D1 promoter. Finally, Mas transformation and some
of Mas signaling (SRF and cyclin D1 but not NF-kB activation) were blocked by dominant negative Rac1.
Taken together, these observations suggest that Mas transformation is mediated in part by activation of
Rac-dependent signaling pathways. Thus, Rho family proteins are common mediators of transformation by a
diverse variety of oncogene proteins that include Ras, Dbl family, and G-protein-coupled oncogene proteins.
G-protein-coupled receptors comprise a large family of cell
surface receptors which mediate the actions of a diverse array
of extracellular ligands, including hormones, neurotransmit-
ters, phospholipids, odorants, photons, and purine nucleotides
(see reference 76 for a review). G-protein-coupled receptors
share a conserved predicted tertiary structure containing seven
transmembrane domains. Intracellular signaling by these re-
ceptors is mediated by one or more members of the heterotri-
meric G protein family. The G protein a subunit cycles be-
tween an inactive GDP-bound form and an active GTP-bound
form, where the inactive a subunit is bound to the receptor and
to a bg heterodimer. Upon ligand stimulation, the receptor
stimulates GDP-GTP exchange to promote the formation of
the GTP-bound a subunit, which then dissociates from both
the receptor and the bg dimer. Both the Ga and bg subunits
then mediate activation of downstream effectors, including ac-
tivation (Gas) or inhibition (Gai) of adenylyl cyclase or acti-
vation of phospholipase C (Gaq or Ga11). bg dimers mediate
a diverse array of effector functions, including activation of the
Ras signal transduction pathway (76).
In addition to mediating a spectrum of normal physiological
responses that include neurotransmission, metabolism, growth,
and differentiation (76), there is also emerging evidence for the
involvement of aberrant G-protein-coupled receptor function
in cellular transformation and oncogenesis (20). For example,
active mutants of the a1B-adrenergic receptor have been
shown to cause transformation of NIH 3T3 cells (2). The
serotonin 5HT1b receptor and the M1, M3, and M5 subtypes of
the acetyl cholinergic receptors were found to cause agonist-
dependent transformation of NIH 3T3 cells (27, 38). Similarly,
deregulated expression of Ga subunits (e.g., Ga12, Ga13, or
Gaq) has also been demonstrated to cause transformation of
rodent fibroblasts (11, 19, 48, 78, 84). Although these Ga
subunits are known to activate specific signaling pathways
which may contribute to mitogenesis, whether involvement of
these signaling pathways promotes the transforming actions of
G-protein-coupled receptors has not been established.
The Mas oncogene was originally identified by its ability to
render NIH 3T3 cells tumorigenic in nude mice (86). Further
studies showed that Mas could promote the growth of rodent
fibroblasts in serum-free medium (3). The predicted tertiary
structure of Mas indicates that it functions as a G-protein-
coupled receptor. Although Mas was once thought to be an
angiotensin II receptor, recent studies argue against this pos-
sibility (3, 10). Thus, the ligand for Mas is presently unknown.
Expression of Mas leads to activation of phospholipase C,
indicating that Mas couples to the Gaq/11 family of heterotri-
meric G proteins (29, 54, 62). However, the signal transduction
pathways activated by Mas, and those that cause cellular trans-
formation, remain unknown.
Among the diverse signaling pathways that mediate G-pro-
tein-coupled receptor function are pathways that lead to acti-
vation of Rho family proteins. Rho proteins constitute a major
branch of the Ras superfamily of small GTPases. To date, at
least 11 distinct mammalian Rho family proteins have been
identified: Rac1, Rac2, RhoA, RhoB, RhoC, RhoD, RhoE,
RhoG, TC10, TTF, and CDC42Hs (41). Like Ras and Ga
subunits, Rho family proteins also function as GDP-GTP bi-
nary switches (6). Rho proteins are activated by guanine nu-
cleotide exchange factors (GEFs; Dbl family proteins) which
stimulate formation of the active, GTP-bound Rho (83). Con-
* Corresponding author. Mailing address: University of North Caro-
lina at Chapel Hill, Lineberger Comprehensive Cancer Center, CB
7295, Chapel Hill, NC 27599-7295. Phone: (919) 966-5634. Fax: (919)
966-0162. E-mail: cjder@med.unc.edu.
† Present address: Signal Pharmaceuticals, Inc., San Diego, CA
92121.
1225
versely, Rho proteins are inactivated by GTPase-activating
proteins which stimulate GTP hydrolysis and formation of the
inactive, GDP-complexed Rho. Additionally, Rho guanine nu-
cleotide dissociation inhibitors inhibit dissociation of GDP and
activation of Rho proteins.
Rho family proteins are regulators of diverse cellular pro-
cesses (41, 69, 74). First, specific Rho family proteins regulate
the organization of the actin cytoskeleton. CDC42Hs stimu-
lates the formation of filopodia, whereas Rac1 induces lamel-
lipodium formation and membrane ruffling, and RhoA causes
the formation of actin stress fibers and focal adhesions (58, 70,
71). Second, Rho family proteins are regulators of gene ex-
pression. Both Rac1 and CDC42Hs are activators of the c-Jun
NH2-terminal kinases (JNKs; also known as stress-activated
protein kinases) and p38 kinase. JNKs activate the c-Jun and
ATF-2 nuclear transcription factors (16, 57, 60), whereas p38
activates ATF-2 (68). For example, a noncanonical AP-1 bind-
ing site in the c-jun promoter is bound and activated by het-
erodimers composed of c-Jun and ATF-2, and this site is stim-
ulated preferentially by JNK-activating signals (4, 33, 77).
Rac1, RhoA, and CDC42Hs activate the serum response fac-
tor (SRF), which together with ternary complex factors (TCFs)
such as the Elk-1 transcription factor stimulates transcription
from serum response elements present in the promoter of c-fos
and other genes (34, 35). TCFs are activated by the p42 and
p44 extracellular signal regulated kinases (ERKs), which to-
gether with JNKs and p38 comprise three distinct members of
the mitogen-activated protein kinase (MAPK) family of pro-
teins. Additionally, Rac1, RhoA, and CDC42 are activators of
NF-kB (61, 73). NF-kB binding sites are present in a wide
variety of promoters, including those that regulate the expres-
sion of genes that promote antiapoptotic responses (5).
Third, Rho family proteins are also regulators of cell prolif-
eration. Rac1, RhoA, and CDC42 function is required for cell
cycle progression and increased expression of the cell cycle
regulator cyclin D1 (60, 81). Fourth, constitutive activation of
RhoA, RhoB, Rac1, and CDC42Hs has been shown to cause
tumorigenic transformation of rodent fibroblasts (43, 64–67),
to promote invasion by T-cell lymphoma cells (Rac1) (28), and
to promote increased motility and invasiveness (28, 56) of
T-47D breast carcinoma cells (Rac1 and CDC42) (40). Finally,
Rho protein function is necessary for the transforming actions
of Ras and Dbl family oncogenes (42–44, 64, 66, 67). However,
what aspect of Rho function contributes to cellular transfor-
mation remains to be resolved.
There is some evidence that Rho proteins are activated by
heterotrimeric G proteins and G-protein-coupled receptors.
First, the muscarinic and angiotensin II receptors, and Ga12,
Ga13, and Gaq, activate JNK, possibly via activation of Rac or
CDC42Hs (14, 15, 32, 63, 88). Second, Rho proteins mediate
the effect of G-protein-coupled receptors on the actin cytoskel-
eton in Swiss 3T3 cells. Lysophosphatidic acid activates RhoA-
mediated induction of stress fiber and focal adhesions. Bom-
besin activates Rac1, leading to lamellipodium formation,
whereas bradykinin activates CDC42Hs, leading to filopodium
formation (46, 58, 70, 71). Finally, microinjection of constitu-
tively activated mutants of Ga12 or Ga13 induced stress fiber
and focal adhesion formation in Swiss 3T3 cells (7, 36). How-
ever, despite these connections, whether the transforming ac-
tions of G-protein-coupled receptors are mediated through
activation of specific Rho family proteins has not been estab-
lished.
Since G-protein-coupled receptors can cause activation of
Rho family proteins, we have addressed the possibility that
specific Rho family proteins also contribute to Mas transform-
ing activity. We observed that Mas expression in NIH 3T3 cells
caused a transformed phenotype that was similar to that seen
with NIH 3T3 cells transformed by constitutively activated
Rac1 and RhoA proteins and distinct from the transformed
phenotype caused by activated Ras. Furthermore, our micro-
injection and immunofluorescence analyses showed that Mas
induced lamellipodia similar to those induced by constitutively
activated Rac1. We also observed that Mas caused activation
of many of the same signal transduction pathways as activated
Rac1: Mas upregulated the activity of JNK, p38, c-Jun, SRF,
cyclin D1, and NF-kB. In contrast to Rac1, Mas activated the
ERK/Elk-1 signaling pathway. Finally, dominant negative
Rac1 blocked Mas transformation and some signaling. We
conclude that Mas transformation is mediated in part by acti-
vation of Rac1 or a Rac-related protein. However, activation of
Rac-independent pathways may also be important for Mas
transformation.
MATERIALS AND METHODS
Molecular constructs. Mas expression constructs were generated by subclon-
ing the BamHI/NsiI fragment from the pM22 construct (genomic sequence) (87)
into the BamHI site of the pZIP-NeoSV(x)1 retrovirus vector, where expression
is under the control of a Moloney long terminal repeat (LTR) promoter, or the
BamHI site of pCDNA3 (Invitrogen), where expression is under the control of
the cytomegalovirus promoter. pAX142-mas was generated by converting the 59
and 39 BamHI sites into blunt ends with T4 DNA polymerase (GIBCO-BRL)
and subcloning into the SmaI site of the pAX142 mammalian expression vector,
where expression is under the control of the elongation factor 1a promoter (82).
pCGN-mas was generated by PCR-mediated DNA amplification to create a 59
BamHI site in frame following the ATG start codon of a hemagglutinin (HA)
epitope tag, where expression is under the control of the cytomegalovirus pro-
moter in the pCGN-hyg mammalian expression vector (75). pZIP-mas (cDNA
sequence) was generated by digesting the StuI/PstI fragment of mas from the
cDNA clone pM242 and subcloning it into the BamHI site of pZIP-NeoSV(x)1
(87). The pZIP-NeoSV(x)1 constructs encoding Ras(61L), H-Ras(WT),
H-Ras(17N), Rac1(61L), Rac1(WT), Rac1(17N), RhoA(63L), RhoA(WT),
RhoA(19N), Raf(340D), and pCGN-hyg constructs encoding Ras(61L) and
Rac1(61L) have been described previously (43, 81). pAX142 constructs encoding
Ras(61L), Rac1(61L), Rac1(WT), Rac1(17N), and RhoA(63L) were generated
by converting the 59 and 39 BamHI sites from the BamHI fragments from the
respective pZIP construct into blunt ends and subcloning the fragments into the
SmaI site of pAX142.
Cell culture and transformation assays. NIH 3T3 cells were grown in Dul-
becco’s modified Eagle medium (DMEM) supplemented with 10% calf serum
(GIBCO-BRL). Cells were transfected by the calcium phosphate precipitation
technique as described previously (12). For the establishment of stable cell lines,
transfected cultures were maintained in growth medium supplemented with 400
mg of G418 (Geneticin; GIBCO-BRL) per ml, and multiple (.100) G418-
resistant colonies were pooled and used for the analyses described. For focus
formation assays, 60-mm-diameter dishes were transfected and maintained in
growth medium for 3 weeks and then stained with 0.4% crystal violet, and the
number of transformed foci was quantitated by visual inspection.
Immunofluorescence analyses. Actin and vinculin staining was performed as
described previously (42). Briefly, cells were plated on glass coverslips, and two
series of stainings were performed. Actin was stained with either tetramethyl
rhodamine isothiocyanate (RITC)-phalloidin or fluorescein isothiocyanate
(FITC)-phalloidin (Molecular Probes). The focal adhesion protein vinculin was
stained with antivinculin monoclonal antibody 7f9 (a gift from Alexeu Belkin)
(26) followed by FITC-conjugated goat anti-mouse immunoglobulin G (Jackson
Immunoresearch Laboratories) or RITC-conjugated donkey anti-mouse immu-
noglobulin G (Chemicon International) (9).
Analysis of lamellipodium formation. Analysis of lamellipodium formation
was performed as described previously (81). Briefly, porcine aortic endothelial
(PAE) cells were coinjected in the nucleus with pCDNA3-mas (100 mg/ml) and
the Green lantern plasmid (Bethesda Research Laboratories) encoding the
green fluorescent protein (25 mg/ml). Rac1(12V), CDC42(12V), and RhoA(12V)
expression plasmids were microinjected in the nucleus at a concentration of 50
mg/ml. Subsequently, cells were starved in serum-free growth medium for 6 h,
fixed, and processed as described previously (81).
Immunoprecipitation and in vitro MAPK assays. ERK, JNK, and p38 kinase
assays were performed as described previously (13, 81). Briefly, Cos-7 cells were
transfected by using the Lipofectamine reagent (GIBCO-BRL) as described by
the manufacturer. Cells were transfected with 1 mg of either pCGN-hyg, pCGN-
ras(61L), pCGN-rac1(61L), or pCGN-mas plasmid DNA along with 1 mg of
plasmid DNA encoding HA epitope-tagged ERK2 (provided by Michael We-
ber), FLAG epitope-tagged JNK1, or FLAG epitope-tagged p38 (provided by
Michael Karin). Thirty-six hours after transfection, cells were serum starved in
DMEM supplemented with 0.5% fetal bovine serum for 12 to 16 h. Cells were
1226 ZOHN ET AL. MOL. CELL. BIOL.
collected in 750 ml of lysis buffer containing protease and phosphatase inhibitors
(80). Protein concentration was determined by using the Bio-Rad protein assay
with bovine serum albumin as a standard, and 250 mg of lysate was used for
immunoprecipitation. Epitope-tagged kinases were immunoprecipitated with ei-
ther anti-HA (BabCo) or anti-FLAG (Kodak Eastman) antibodies and protein
A/G-agarose beads (Santa Cruz Biotechnology).
Kinase assays were performed as described previously with myelin basic pro-
tein and glutathione S-transferase (GST)-conjugated c-Jun [GST–c-Jun(1-79)]
and GST–ATF-2(1-254) as substrates for the ERK2, JNK1, and p38 kinase
assays, respectively. Reactions were stopped with 23 Laemmli sample buffer and
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). Proteins were transferred to Immobilon membranes (Millipore), and
the membranes were then exposed to film. Incorporated radioactivity was quan-
titated on a PhosphorImager (Molecular Dynamics). For standardization of
transfection efficiency, 25 mg of total cell protein was analyzed by Western blot
analysis as described previously (13, 81).
Transient expression reporter assays. Transcriptional activation of luciferase
gene expression constructs was performed as described previously (30). Briefly,
NIH 3T3 cells were transfected with the indicated plasmid DNAs by the calcium
phosphate coprecipitation method (12). The growth medium was then replaced
with DMEM supplemented with 0.5% calf serum (GIBCO-BRL). Forty-eight
hours after transfection, cells were lysed in 300 ml of luciferase lysis buffer
(Amersham), and 25 to 50 ml of lysate was analyzed by using enhanced chemi-
luminescence reagents and a Monolight 2010 luminometer (Analytical Lumines-
cence).
The reporter constructs Gal4–Elk-1 (30), 5X Gal4-Luc (72), (SREm)2-Luc
(81), cyclin D1-Luc (1), and HIV-Luc (25) have been described previously.
Gal4–Elk-1 encodes a chimeric protein that contains the Gal4 DNA binding
domain together with the transcriptional activation domain of Elk-1. The
(SREm)2-Luc construct contains the luciferase gene where expression is con-
trolled by a minimal promoter with a mutated serum response element from the
c-fos promoter. HIV-Luc contains the luciferase gene where expression is con-
trolled by a minimum promoter and tandem copies of the NF-kB binding sites
from the human immunodeficiency virus (HIV) LTR promoter. The cyclin D1-
Luc construct consists of the luciferase gene where expression is controlled by
sequences from 2963 of the human cyclin D1. The Jun2Luc reporter plasmid
contains three tandem copies of the Jun/ATF-2 DNA binding motif present in
the c-jun promoter introduced into HindIII and SalI sites in the minimal c-fos
promoter in the D56dEFos-luciferase reporter plasmid using the following oli-
gonucleotides: 59 AGC TAG CAT TAC CTC ATC CC 39 (top strand) and
59TCG AGG GAT GAG GTA ATG CT 39 (24).
RESULTS
Overexpression of Mas in NIH 3T3 cells has been shown to
promote cell growth in serum-free growth medium and tumor
formation when introduced into nude mice (3, 87). We ob-
served that the transformed foci induced by coexpression of
Mas were very distinct from those caused by activated Ras or
Src. Instead, they were similar to those caused by constitutively
activated mutants of Rac1 or RhoA as well those caused by
Dbl family oncoproteins such as Dbl or Vav (42). As shown in
Fig. 1A, in a primary focus assay, activated Ras(61L) induced
large foci which contained highly refractile spindle-shaped
cells, while activated RhoA(63L) or Mas induced foci which
contained densely packed nonrefractile cells. However, the
appearance of a Mas-induced focus was not identical to that of
a RhoA-induced focus: foci caused by RhoA were large and
diffuse, while the foci caused by Mas were more punctate.
Furthermore, Mas focus-forming activity was much greater
than that seen with either activated Rho or Rac. In particular,
activated Rac1 mutants (12V, 61L, and 115I) do not show
focus-forming activity in a primary NIH 3T3 focus formation
assay. Instead, activating mutants of Rac1 form foci only after
they are selected, thus enriching the cell population for cells
which may express higher levels of the Rac protein (43).
We next compared the transformed morphology of Mas-
expressing cells with that of cells transformed by activated Ras,
Rac1, or RhoA. For these analyses, NIH 3T3 cells were stably
transfected with plasmid DNAs encoding either Ras(61L),
RhoA(63L), Rac1(115I), or Mas or the empty pZIP vector
FIG. 1. Mas-transformed cells exhibit a transformed phenotype similar to those of Rac- and Rho-transformed cells. (A) Transformed foci from NIH 3T3 cultures
transfected with pZIP-ras(61L), pZIP-rhoA(63L), and pZIP-mas. (B) Morphology of NIH 3T3 cells stably transfected with pZIP-NeoSV(x)1, pZIP-ras(61L),
pZIP-rac1(115I), and pZIP-mas. Multiple (.100) G418-resistant colonies were pooled to establish the cell lines used for these analyses.
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control, and multiple (.100) G418-resistant colonies were
then pooled. As we have described previously, Rac1(115I)- and
RhoA(63L)-expressing cells retained the nonrefractile and ad-
herent characteristics of nontransformed NIH 3T3 cells, while
Ras(61L)-expressing cells were spindle shaped, less adherent,
and highly refractile (Fig. 1B) (42, 43). We observed that
Mas-transformed cells exhibited a morphology that was most
similar to that of Rac- or Rho-transformed cells. Although
Mas-transformed cells were slightly more refractile in appear-
ance and exhibited a more elongated morphology than that
seen with the Rac1- or RhoA-transformed cells, the appear-
ance of Mas-transformed cells was still very distinct from that
of Ras-transformed cells.
Coexpression of Mas with Raf causes synergistic enhance-
ment of transforming activity. We and others have shown that
coexpression of activated Rho family proteins or GEFs with
activated Raf causes a synergistic enhancement of focus-form-
ing activity (42–44, 65, 66). Therefore, we determined if Mas
could also cooperate with activated Raf. For these analyses, we
used the weakly activated Raf(340D) mutant protein (21). As
we have shown previously, transfection of expression vectors
encoding either activated Rac1(115I) or Raf(340D) alone in-
duced very few or no foci in NIH 3T3 cells (Fig. 2). However,
the coexpression of activated Rac1 with Raf(340D) caused a
greater than 30-fold enhancement of focus-forming activity.
Similarly, coexpression of Mas with Raf(340D) caused syner-
gistic enhancement of focus-forming activity (greater than
threefold above additive). These results indicate that Mas, like
Rac1, can cooperate with activated Raf-1 and cause synergistic
focus-forming activity.
In addition to a synergistic enhancement of focus-forming
activity, coexpression of activated Raf enhanced the size of foci
and altered the appearance of cells within the foci induced by
Rac1, RhoA, and Mas. The morphologies of cells within foci
induced by coexpression of activated Raf with either Mas or
activated Rac1 were similar to each other but distinct from
those induced by coexpression of activated Raf and RhoA. The
Raf-RhoA-induced foci contained elongated, refractile cells
that were similar in appearance to cells in Ras-induced foci. In
contrast, the Raf-Rac1- and Raf-Mas-induced foci contained
cells that had a refractile appearance but lacked the elongated
shape seen with Ras or Raf plus RhoA foci (data not shown).
Mas and Rac cause similar changes in actin cytoskeletal
arrangement. Immunofluorescence analysis was done on NIH
3T3 cells which stably expressed activated Ras, Rac1, and Mas
to visualize actin stress fibers or focal adhesions (Fig. 3A). As
we have reported previously, cells transformed by activated
RhoA(63L) exhibited enhanced stress fibers and focal adhe-
sions, whereas cells transformed by activated Rac1(115I) re-
tained stress fibers and focal adhesions but also exhibited
membrane ruffling (42). In contrast, Ras(61L)-transformed
cells showed a loss of stress fibers and focal adhesions but also
exhibited membrane ruffling. The actin cytoskeletal arrange-
ment of Mas-transformed cells most closely resembled that of
Rac-transformed cells. Mas-transformed cells retained stress
fibers and focal adhesions and exhibited increased membrane
ruffling.
Our immunofluorescence analysis of Mas-transformed cells
suggested that Mas activated Rac proteins. To address this
further, we determined if microinjection of Mas could induce
the same changes in actin cytoskeletal organization as acti-
vated Rac1. For these analyses, we microinjected expres-
sion vectors encoding Mas, Rac1(12V), RhoA(14V), and
CDC42Hs(12V) into PAE cells. We observed similar results
with Rac1(12V) as with the 61L and 115I activating mutants.
As described previously, RhoA induced stress fiber formation
(70) and CDC42Hs(12V) induced filopodium formation (data
not shown), whereas Mas induced lamellipodium formation
similar to that induced by Rac1(12V) (Fig. 3B). These results
suggest that Mas activates Rac1 or a Rac-related protein
rather than RhoA or CDC42.
Mas and Rac stimulate common signal transduction path-
ways. If Mas transforms NIH 3T3 cells by activation of Rac or
a Rac-related protein, then Mas should also stimulate the same
signal transduction pathways as activated Rac. To evaluate this
possibility, we used two approaches. First, we and others have
found that expression of activating mutants of Rac1 and
CDC42Hs increases the kinase activity of the MAPK family
members JNK and p38 but not ERKs, while RhoA does not
activate any of these MAPKs when assayed in NIH 3T3 or
Cos-7 cells (16, 57, 60). Therefore, if Mas activates Rac1 or a
Rac-related protein, we would predict that Mas would also
increase JNK and p38, but not ERK, kinase activity. Second,
activated Rac1 has been shown to stimulate transcription from
a variety of promoter elements that include a mutated version
of the serum response element of the c-fos promoter that no
longer binds TCFs, the c-Jun/ATF-2-responsive element of the
c-jun promoter, the NF-kB-responsive element of the HIV
LTR promoter, and the cyclin D1 promoter (35, 61, 73, 81).
Therefore, we determined if Mas also stimulated transcription
from these promoter elements and, if so, whether dominant
negative Rac1(17N) could selectively block activation of these
promoters.
For analysis of MAPK activation, we cotransfected Cos-7
cells with plasmid DNA encoding Ras(61L), Rac1(61L), or
Mas, together with plasmid DNA encoding epitope-tagged
p38, JNK1, or ERK2/p42MAPK. The epitope-tagged kinases
were immunoprecipitated, and kinase activity was determined
as described previously (13, 81). As shown in Fig. 4, Mas
caused a 3.3-fold increase in JNK kinase activity, similar to the
4.2-fold increase induced by Ras(61L), whereas Rac1(61L)
caused a 13.6-fold activation of JNK. Similarly, Mas caused a
6.5-fold increase in p38 kinase activity, which was comparable
to the 5.8- and 6.8-fold increases caused by Ras(61L) and
Rac1(61L), respectively. In contrast to Ras(61L), Rac1(61L)
and Mas did not cause a significant stimulation of ERK2 ac-
tivity (Fig. 4C). However, we did observe that Mas caused a
reproducible but weak activation of ERK2 (less than 1.5-fold)
FIG. 2. Like Rac1, Mas cooperates with Raf(340D) and causes synergistic
focus-forming activity. NIH 3T3 cells were cotransfected with pZIP expression
plasmids encoding the indicated proteins. One hundred nanograms of pZIP-mas
cDNA and 1 mg of all other DNAs were transfected per 60-mm-diameter dish.
The data are shown as mean 6 standard error for triplicate plates and are
representative of at least three separate experiments.
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FIG. 3. Mas and Rac1 cause similar changes in the organization of the actin cytoskeleton. (A) Mas- and Rac-transformed cells retain stress fibers and show
enhanced membrane ruffling. Stably transfected NIH 3T3 cell lines expressing the indicated proteins were subject to immunofluorescence analysis as described in
Materials and Methods. Shown are actin stress fibers and focal adhesions stained with RITC-phalloidin and FITC-antivinculin antibodies, respectively. Membrane
ruffles are indicated by arrowheads. (B) Like Rac1(12V), Mas induces membrane ruffles in PAE cells. PAE cells were microinjected with expression constructs encoding
either Mas along with GFP (a and b) or Myc epitope-tagged Rac1(12V) (c and d) as described in Materials and Methods. Cells were serum starved following injection,
and actin was stained with RITC-phalloidin (a and c). Microinjected cells were identified by expression of GFP (for Mas) (b) or anti-Myc antiserum (for Rac1) (d).
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that was never seen with Rac1. Thus, Mas may stimulate a
Rac-independent pathway leading to activation of ERK2.
We next determined if, like Rac, Mas could stimulate tran-
scription from reporter constructs where luciferase expression
was controlled by minimal promoters containing recognition
sites for SRF, c-Jun/ATF-2, and NF-kB. For these analyses, we
cotransfected plasmid DNAs encoding Mas, activated Rac1,
RhoA, and Ras along with the indicated reporter constructs.
Mas, like activated Rac1, stimulated transcription from these
Rac-responsive elements (Fig. 5A to C). Both Rac1(61L) and
Mas caused a greater than 100-fold stimulation of SRF, 5-fold
or greater activation of NF-kB, and 10-fold or greater stimu-
lation of c-Jun/ATF-2. Additionally, we showed recently that
activated Rac1, as well as RhoA, stimulated transcription from
the cyclin D1 promoter (81). Like Rac1, Mas stimulated tran-
scription from the cyclin D1 promoter (Fig. 5D). Thus, Mas
and Rac1 activate signaling pathways that stimulate transcrip-
tion from common DNA promoter elements.
We also determined if Mas could activate the Elk-1 tran-
scription factor by cotransfection of a plasmid encoding the
Gal4 DNA binding domain fused to the transcription activa-
tion domain of Elk-1 (Gal4–Elk-1) together with a second
plasmid where luciferase gene expression is controlled by a
minimum promoter that contains tandem Gal4 DNA binding
sequences (5XGal4-Luc). In contrast to Rac1, Mas caused a
slight (30-fold) activation of Elk-1 activity, while Ras(61L)
caused a 180-fold increase in activity (Fig. 6). These results
along with the slight increase in ERK2 activation observed in
the kinase assay (Fig. 4C) indicate that Mas can also activate
Rac-independent signaling pathways which may also contrib-
ute to Mas transformation.
To establish if activation of these signaling pathways by Mas
was dependent on Rac1 function, we determined if Mas stim-
ulation of transcription from SRF- or NF-kB-responsive pro-
moters, or the cyclin D1 promoter, could be blocked by coex-
pression of dominant negative Rac1 (Fig. 7). For these
analyses, we performed transient expression assays where Mas
was expressed either alone or together with Rac1(WT) or Rac1
(17N). We observed that coexpression of Rac1(17N) de-
creased the ability of Mas to stimulate transcription from both
the SRF and the cyclin D1 promoter reporter plasmids by 70%
(Fig. 7A and B). Coexpression of Rac1(WT) had no effect or
caused a slight enhancement of stimulation. Thus, signaling by
Mas to SRF and the cyclin D1 promoter is dependent on Rac
function. In contrast to the requirement for Rac1 for SRF and
cyclin D1 activation, coexpression of dominant negative Rac1
FIG. 4. Mas and Rac are strong activators of p38 and JNK but not ERK. (A)
Activation of ERK2 by Mas. Cos-7 cells were transfected with either pCGN-hyg
(vector), pCGN-ras(61L), pCGN-rac1(61L), or pCGN-mas along with an HA
epitope-tagged ERK2 expression vector. Immunocomplex kinase assays with
myelin basic protein (MBP) as a substrate were performed following immuno-
precipitation of HA-ERK2 (top panel). Fold activation (Act) (middle panel) of
ERK was determined by PhosphorImager analysis and expressed relative to
phosphorylation levels in vector-transfected cells. Twenty-five micrograms of
lysate was resolved by SDS-PAGE, transferred to an Immobilon membrane, and
subsequently probed with anti-HA antibody to ensure equivalent expression
levels of HA-ERK2 (bottom panel). (B) Activation of JNK1 by Mas. Cos-7 cells
were transfected as for panel A but with FLAG epitope-tagged JNK1. JNK1
kinase activity was determined with GST–c-Jun(1-79) as a substrate (top panel).
Fold activation (middle panel) and JNK1 levels (bottom panel) were determined
as described for panel A. Data in panels A and B are representative of at least
three independent experiments in Cos-7 and NIH 3T3 cells, using pCGN and
pCDNA3 expression plasmids. (C) Activation of p38 by Mas. Cos-7 cells were
transfected as described for panels A and B but with FLAG epitope-tagged p38.
p38 kinase activity was determined with GST–ATF-2(1-254) as a substrate (top
panel); fold activation (middle panel) and p38 expression levels (bottom panel)
were determined as described above. Data are representative of two separate
experiments.
FIG. 5. Mas and Rac stimulate transcription from common promoter ele-
ments. NIH 3T3 cells were transfected with pAX142 (vector), pAX142-ras(61L),
pAX142-rac1(61L), pAX142-rhoA(63L), or pAX142-mas along with luciferase
gene reporter constructs for SRF transcriptional activity (A), NF-kB transcrip-
tional activity (B), c-Jun/ATF-2 transcriptional activity (C), and cyclin D1 ex-
pression (D). Data shown are representative of at least three independent ex-
periments using both pAX142 and pCDNA3 mammalian expression constructs.
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did not inhibit Mas stimulation of transcription from the
NF-kB reporter plasmid (Fig. 7C). Thus, although Rac1 has
been shown to be an activator of NF-kB (61, 73), Mas activa-
tion of NF-kB does not appear to be dependent on Rac func-
tion.
Mas requires Rac, Rho, and Ras for transformation. The
data described above support the hypothesis that Mas activates
Rac1. To address the role of Rac1 function in Mas transfor-
mation, we determined if Rac1 function is required for trans-
formation by Mas. For these analyses, NIH 3T3 cells were
transfected with the Mas expression plasmid either alone or
together with expression plasmids encoding wild-type or dom-
inant negative Rac1. Coexpression of dominant negative, but
not wild-type, Rac1 caused a 60% reduction in Mas-induced
foci (Fig. 8). Together with our actin cytoskeletal and signaling
analyses, these results suggest that Mas transformation and
signaling are mediated by activation of Rac or a Rac-related
protein. Finally, we found that coexpression of dominant neg-
ative Ras and RhoA also impaired Mas focus-forming activity
(Fig. 8). These results suggest that RhoA and Ras function
may be required for Mas transformation.
DISCUSSION
The Mas oncogene was identified originally as a gene that
encodes a novel G-protein-coupled receptor that caused tu-
morigenic transformation of NIH 3T3 cells (87). However, the
signaling pathways that mediate Mas transforming activity
have not been determined. We observed that Mas caused the
appearance of transformed foci of cells that were similar to
those caused by constitutively activated Rho family proteins.
We determined that Mas and Rac1 induced similar changes in
the actin cytoskeleton that included the induction of lamelli-
podia and membrane ruffles. Furthermore, like Rac1, Mas
caused strong activation of the MAPK family members JNK
and p38 but not ERK. Mas and Rac1 also stimulated transcrip-
tion from the same DNA promoter elements, including NF-
kB, SRF, c-Jun/ATF-2, and the cyclin D1 promoter. Finally,
Mas transformation and some signaling were impaired by co-
expression of the Rac1(17N) dominant negative protein.
Taken together, these results strongly suggest that Mas trans-
formation is promoted by activation of Rac or a Rac-related
protein. However, since we did observe quantitative (potency
of focus-forming activity) and qualitative (activation of ERK
and Elk-1 and Rac-independent activation of NF-kB) differ-
ences between Mas and Rac1, we also suggest that Mas trans-
FIG. 6. Mas, but not Rac1, caused activation of Elk-1. NIH 3T3 cells were
transfected with pAX142 (vector), pAX142-ras(61L), pAX142-rac1(61L),
pAX142-rhoA(63L), or pAX142-mas along with Gal4–Elk-1 and the Gal4-re-
sponsive 5XGal4-Luc construct. Data shown are representative of at least three
independent experiments using both pAX142 and pCDNA3 mammalian expres-
sion constructs.
FIG. 7. Dominant negative Rac1 blocks Mas signaling. NIH 3T3 cells were cotransfected with pAX142-mas and either pAX142-rac1(17N) or pAX142-rac1(WT)
along with luciferase gene reporter constructs for SRF (A), cyclin D1 (B), or NF-kB (C) expression. Data are expressed as the mean of the percentage of the activation
in the Mas-plus-vector samples 6 standard deviation of duplicate samples and are representative of at least two independent experiments.
FIG. 8. Dominant negative Rac, RhoA, and Ras block Mas transformation.
NIH 3T3 cells were transfected with pZIP-mas and the indicated wild-type (WT)
and dominant negative Rho family proteins, and the focus formation assay was
performed as described in Materials and Methods. Data are expressed as the
mean of the percentage of the total number of foci in the Mas-plus-vector
dishes 6 standard error and are the average of six separate experiments per-
formed in duplicate or triplicate.
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formation may be mediated by Rac-independent signaling
pathways as well.
Our first indication that Mas transformation may be medi-
ated by the activation of Rho family proteins came from the
appearance of the foci of transformed cells caused by Mas in
the NIH 3T3 focus formation assay and the morphology of
Mas-transformed cells. We and others observed that constitu-
tively activated mutants of Rac1, RhoA, and RhoB caused the
appearance of transformed foci that were very distinct from
those caused by oncogenic Ras, activated tyrosine or serine/
threonine kinases, or transcription factors (43, 64–67, 81).
RhoA- or Rac-induced foci retain a nonrefractile appearance
and consist of tightly packed clusters of cells, whereas Ras-
induced foci are large and well spread and contain highly
refractile spindle-shaped cells. Dbl family proteins, such as Dbl
and Vav, that function as Rho GEFs cause the appearance of
Rho-like foci (42). Similarly, foci induced by constitutively
activated mutants of Ga12 and G13, which are activators of
Rho, induce Rho-like foci (11, 37, 78, 79, 84, 85). Furthermore,
effector domain mutants of Ras that no longer bind to or
activate the Raf-1 serine/threonine kinase [e.g., Ras(12V,
40C)] but retain Rho-dependent functions also induce Rho-
like foci (44). Finally, the morphology of cells stably expressing
activated Rac1, RhoA, or Rho family activators, such as Dbl,
Vav, Ga12, or Ga13, is distinct from that of cells expressing
Ras. These cells retain a flat nonrefractile appearance which is
unlike the highly refractile appearance of cells transformed by
activated Ras (42–44). Thus, we have observed that the induc-
tion of Rho-like foci in NIH 3T3 cells and a lack of significant
morphological transformation have been reliable indicators
that transformation may involve activation of Rho family pro-
teins.
In addition to the appearance of Rac-like foci, further evi-
dence that Mas transformation is mediated by activation of a
specific Rho family protein was provided by the cooperative
transforming activity observed when Mas was coexpressed with
activated Raf. We and others observed that coexpression of
activated Raf-1 together with activated Rac1 or RhoA caused
a synergistic enhancement of focus-forming activity (43, 64, 65,
67). Additionally, coexpression of activated Raf-1 with Rho
activators such as activated Dbl family proteins, Ga12, Ga13,
and Ras effector domain mutants which are defective in Raf
binding causes synergistic enhancement of focus-forming ac-
tivity (11, 42, 44). This cooperation between Raf and Rho
family proteins is believed to reflect the fact that full Ras
transforming activity is mediated by the coordinate activation
of Raf and a Raf-independent pathway(s) that leads to activa-
tion of Rho family proteins.
Key evidence that Mas specifically activated Rac or a Rac-
related protein was provided by our analyses of the actin cy-
toskeletal arrangement in NIH 3T3 cells which constitutively
overexpress Mas. Mas-transformed cells showed enhanced
membrane ruffling, which is a hallmark of Rac activation (71).
Similarly, microinjection analyses in PAE cells showed that
Mas induced the same changes in actin cytoskeletal organiza-
tion as activated Rac, which were distinct from those caused by
activated RhoA or CDC42. Therefore, in two separate cell
types, Mas and Rac induced similar changes in the organiza-
tion of the actin cytoskeleton.
Additional evidence implicating Rac or a Rac-related pro-
tein in Mas function was revealed by our comparison of Rac
and Mas signaling activities. Like activated Rac1, Mas stimu-
lated the strong activation of the MAPK family members JNK
and p38, but not ERK, whereas RhoA(61L) is not an activator
of any of these MAPK family members (16, 57, 60). Further-
more, both Rac1 and Mas stimulated transcription from a
panel of reporter plasmids which contained Rac-responsive
DNA elements, including the NF-kB-, Jun/ATF-2-, and SRF-
responsive elements and the cyclin D1 promoter. Mas activa-
tion of SRF and cyclin D1 expression was blocked specifically
by dominant negative Rac1. Interestingly, Mas activation of
NF-kB was not blocked by dominant negative Rac1. Thus,
although activated Rac1 has been shown to stimulate NF-kB
transcription (61, 73), Mas activation of NF-kB may be medi-
ated by a Rac-independent pathway.
We found that Mas focus-forming activity was greatly inhib-
ited by coexpression of dominant negative Rac1. This result,
taken together with our cytoskeleton and signaling analyses,
strongly suggests that Mas signaling and transformation are
mediated by its ability to activate Rac or a Rac-related protein.
However, we observed that Mas transformation was also im-
paired by dominant negative RhoA, suggesting that RhoA
function may also be necessary for full Mas transforming ac-
tivity. This requirement may reflect the fact that activated Rac1
can activate RhoA function (71). Alternatively, Rho may be
required for an autocrine loop that is essential for Mas trans-
formation.
Although our actin cytoskeleton and signaling analyses im-
plicate Rac1 as a necessary component of Mas function, we
cannot exclude the possibility that Mas is an activator of an as
yet to be identified Rac-related protein. A definitive demon-
stration that Rac proteins are activated by Mas will require an
analysis showing that Rac1-GTP levels are elevated in Mas-
transformed cells. However, our present efforts to perform this
analysis has been hampered by the lack of anti-Rac antibodies
that would be useful in such assays.
We found that dominant negative Ras also impaired Mas
focus-forming activity, suggesting that Ras function may also
be important for Mas transformation. The possibility that Ras
is activated in Mas-transformed cells is suggested by our ob-
servation that Mas caused a reproducible, but weak, activation
of ERK which was not caused by activated Rac1. Similarly, like
activated Ras, we found that Mas, but not Rac1, caused acti-
vation of Elk-1 (Fig. 6). Elk-1 is phosphorylated and activated
by ERKs (51). Additionally, activated Rac can also synergize
with activated Raf to increase ERK2 activity (23). Thus, it is
possible that Mas causes a weak activation of the
Ras3Raf3MEK3ERK3Elk-1 pathway that contributes to
Mas transforming activity. This idea may explain some of the
differences that we have observed between Mas and Rac trans-
forming activity: the far greater potency of Mas than of Rac1
in focus formation assays, the weaker synergy seen between
Mas and activated Raf, and the more refractile and spindle-
shaped appearance of Mas-transformed cells. G-protein-cou-
pled receptors such as the M1-muscarinic acetylcholine recep-
tor have been reported to activate ERK1/2 by two mechanisms:
activation of protein kinase C via Gaq or increased phospho-
lipase C activity and activation of Ras via release of bg sub-
units (18, 22, 31, 45, 49; see reference 76 for a review). Further
experimentation will be required to determine if Mas activates
Ras and if it is mediated through activated Ga versus bg
subunits.
At present, the G protein(s) which couples Mas to Rac
activation is not known. One logical candidate is Gaq, a pos-
sibility supported by several observations. First, Mas has been
shown to be an activator of phospholipase C (29, 54, 62), which
is an effector of Gaq (76). Second, bombesin receptor activa-
tion causes activation of phospholipase C (59), and activation
of this receptor causes a Rac-dependent induction of lamelli-
podia (71). Third, the stimulation of two Gaq-coupled recep-
tors, the angiotensin II and M1-muscarinic acetylcholine recep-
tors, and activated Gaq itself, leads to activation of JNK (15,
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32, 88). Lastly, constitutively activated Gaq causes transforma-
tion of NIH 3T3 cells (19, 39). However, we have found that
microinjection of a constitutively activated Gaq mutant did not
cause induction of lamellipodia and instead stimulated stress
fiber formation in porcine aortic endothelial cells (89). There-
fore, while Gaq may mediate some aspects of Mas function, it
does not appear to be the link that connects Mas with Rac, at
least in PAE cells. Other possible Ga subunits that may pro-
vide such a connection are Ga12 and Ga13. Both also exhibit
Rho-like transforming activities in NIH 3T3 cells (11, 37, 84,
85) and have been shown to activate JNK (14, 63). However,
microinjection analyses of activated Ga12 and Ga13 in Swiss
3T3 cells caused the induction of stress fibers rather than
lamellipodia (7, 36). Thus, these two Ga subunits do not seem
to provide the connection between Mas and Rac. Whether a
novel Ga family protein is involved in the signaling pathway
that promotes Mas activation of Rac remains to be deter-
mined. Alternatively, bg subunits may mediate Mas activation
of Rac. In Cos-7 cells, overexpression of bg subunits potently
induced JNK activity (17). Finally, it is likely that a Dbl family
protein is required to mediate Mas activation of Rac. To date,
several Dbl family proteins which have exchange activity for
Rac1 (e.g., Tiam-1) have been described and represent possi-
ble candidates for mediating Mas activation of Rac (see refer-
ence 83 for a review). To address this possibility, we are pres-
ently evaluating whether dominant negative mutants of specific
Dbl family proteins can block Mas signaling and transforma-
tion.
In rodents, Mas transcripts are expressed primarily in the
brain, with the highest detected levels in the cerebral cortex,
the hippocampus (dentate gyrus and CA3 and CA1 cell layers),
the piriform cortex, and the olfactory bulb (8, 52, 55, 86).
Expression of Mas is developmentally regulated and begins
postnatally on day 1 in postmitotic neurons, continuing
through adulthood. In the dentate gyrus and the CA1 layers in
the hippocampus, Mas is expressed at a time in development
when most neurons are postmitotic but have not begun extend-
ing their axons (52). Additionally, Mas mRNA expression is
upregulated by seizure activity in the dentate gyrus and CA1
fields of the hippocampus (53). The selectivity and timing of
Mas expression in plastic regions of the brain and its regulation
by neuronal activity suggest that Mas may play a role in growth
and plasticity in these regions. Therefore, Mas may function as
a cell surface receptor to regulate synapse formation in the
brain. The observation that Mas can activate Rac proteins,
leading to lamellipodium formation in both fibroblasts and
endothelial cells, may provide an insight into the function of
Mas in the nervous system. Accumulating evidence suggests
that Rac proteins are involved in growth cone formation in
developing neurons (47, 50). These observations, taken to-
gether with the fact that Mas is expressed in developing neu-
rons and in neurons which may be undergoing plastic changes,
suggest a model where Mas may regulate growth cone forma-
tion by activation of Rac proteins. Experiments to determine if
Mas can regulate growth cone formation in differentiating neu-
rons will be necessary to address this possibility.
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